Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147,159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. Wang L, et al. J Exp Med. 2024 Mar 4;221(3):e20231519. doi: 10.1084/jem.20231519. Epub 2024 Feb 9. J Exp Med. 2024. PMID: 38334978 Free PMC article.
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
Monga V, Miller BJ, Tanas M, Boukhar S, Allen B, Anderson C, Stephens L, Hartwig S, Varga S, Houtman J, Wang L, Zhang W, Jaber O, Thomason J, Kuehn D, Rajput M, Metz C, Zamba KD, Mott S, Abanonu C, Bhatia S, Milhem M. Monga V, et al. Among authors: wang l. J Immunother Cancer. 2021 Jul;9(7):e003119. doi: 10.1136/jitc-2021-003119. J Immunother Cancer. 2021. PMID: 34330766 Free PMC article. Clinical Trial.
147,159 results
You have reached the last available page of results. Please see the User Guide for more information.